[18F]fluorodeoxyglucose uptake by positron emission tomography for diagnosis of suspected lung cancer

Impact of verification bias

Michael S. Lauer, Sudish C. Murthy, Eugene H. Blackstone, Ikenna Okereke, Thomas W. Rice

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: Verification bias occurs when test findings influence the decision to perform a gold standard test. It adversely influences diagnostic test accuracy by inflating sensitivity and deflating specificity.Westudied the impact of verification bias on the estimated accuracy of a test commonly used in suspected lung cancer. Methods: We studied 534 consecutive patients referred for [18F]fluorodeoxyglucose uptake by positron emission tomography (PET). Primary outcomes were tissue diagnoses of cancer and of mediastinal lymph node metastases. A secondary outcome was 3-year mortality. We accounted for verification bias using 2 validated methods. Results: The gold standard test, namely tissue acquisition, was performed in 419 patients (78%); mediastinal lymph node sampling occurred in 301 (56%). While the 410 patients with PET-diagnosed stage I cancer or higher were more likely than patients with negative PET scan findings to undergo tissue diagnosis testing (92% vs 34%) (P

Original languageEnglish (US)
Pages (from-to)161-165
Number of pages5
JournalArchives of Internal Medicine
Volume167
Issue number2
DOIs
StatePublished - Jan 22 2007
Externally publishedYes

Fingerprint

Fluorodeoxyglucose F18
Positron-Emission Tomography
Lung Neoplasms
Mediastinal Neoplasms
Lymph Nodes
Routine Diagnostic Tests
Neoplasm Metastasis
Sensitivity and Specificity
Mortality
Neoplasms

ASJC Scopus subject areas

  • Internal Medicine

Cite this

[18F]fluorodeoxyglucose uptake by positron emission tomography for diagnosis of suspected lung cancer : Impact of verification bias. / Lauer, Michael S.; Murthy, Sudish C.; Blackstone, Eugene H.; Okereke, Ikenna; Rice, Thomas W.

In: Archives of Internal Medicine, Vol. 167, No. 2, 22.01.2007, p. 161-165.

Research output: Contribution to journalArticle

Lauer, Michael S. ; Murthy, Sudish C. ; Blackstone, Eugene H. ; Okereke, Ikenna ; Rice, Thomas W. / [18F]fluorodeoxyglucose uptake by positron emission tomography for diagnosis of suspected lung cancer : Impact of verification bias. In: Archives of Internal Medicine. 2007 ; Vol. 167, No. 2. pp. 161-165.
@article{dec4f10239a6416680ea67f99463eee8,
title = "[18F]fluorodeoxyglucose uptake by positron emission tomography for diagnosis of suspected lung cancer: Impact of verification bias",
abstract = "Background: Verification bias occurs when test findings influence the decision to perform a gold standard test. It adversely influences diagnostic test accuracy by inflating sensitivity and deflating specificity.Westudied the impact of verification bias on the estimated accuracy of a test commonly used in suspected lung cancer. Methods: We studied 534 consecutive patients referred for [18F]fluorodeoxyglucose uptake by positron emission tomography (PET). Primary outcomes were tissue diagnoses of cancer and of mediastinal lymph node metastases. A secondary outcome was 3-year mortality. We accounted for verification bias using 2 validated methods. Results: The gold standard test, namely tissue acquisition, was performed in 419 patients (78{\%}); mediastinal lymph node sampling occurred in 301 (56{\%}). While the 410 patients with PET-diagnosed stage I cancer or higher were more likely than patients with negative PET scan findings to undergo tissue diagnosis testing (92{\%} vs 34{\%}) (P",
author = "Lauer, {Michael S.} and Murthy, {Sudish C.} and Blackstone, {Eugene H.} and Ikenna Okereke and Rice, {Thomas W.}",
year = "2007",
month = "1",
day = "22",
doi = "10.1001/archinte.167.2.161",
language = "English (US)",
volume = "167",
pages = "161--165",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "2",

}

TY - JOUR

T1 - [18F]fluorodeoxyglucose uptake by positron emission tomography for diagnosis of suspected lung cancer

T2 - Impact of verification bias

AU - Lauer, Michael S.

AU - Murthy, Sudish C.

AU - Blackstone, Eugene H.

AU - Okereke, Ikenna

AU - Rice, Thomas W.

PY - 2007/1/22

Y1 - 2007/1/22

N2 - Background: Verification bias occurs when test findings influence the decision to perform a gold standard test. It adversely influences diagnostic test accuracy by inflating sensitivity and deflating specificity.Westudied the impact of verification bias on the estimated accuracy of a test commonly used in suspected lung cancer. Methods: We studied 534 consecutive patients referred for [18F]fluorodeoxyglucose uptake by positron emission tomography (PET). Primary outcomes were tissue diagnoses of cancer and of mediastinal lymph node metastases. A secondary outcome was 3-year mortality. We accounted for verification bias using 2 validated methods. Results: The gold standard test, namely tissue acquisition, was performed in 419 patients (78%); mediastinal lymph node sampling occurred in 301 (56%). While the 410 patients with PET-diagnosed stage I cancer or higher were more likely than patients with negative PET scan findings to undergo tissue diagnosis testing (92% vs 34%) (P

AB - Background: Verification bias occurs when test findings influence the decision to perform a gold standard test. It adversely influences diagnostic test accuracy by inflating sensitivity and deflating specificity.Westudied the impact of verification bias on the estimated accuracy of a test commonly used in suspected lung cancer. Methods: We studied 534 consecutive patients referred for [18F]fluorodeoxyglucose uptake by positron emission tomography (PET). Primary outcomes were tissue diagnoses of cancer and of mediastinal lymph node metastases. A secondary outcome was 3-year mortality. We accounted for verification bias using 2 validated methods. Results: The gold standard test, namely tissue acquisition, was performed in 419 patients (78%); mediastinal lymph node sampling occurred in 301 (56%). While the 410 patients with PET-diagnosed stage I cancer or higher were more likely than patients with negative PET scan findings to undergo tissue diagnosis testing (92% vs 34%) (P

UR - http://www.scopus.com/inward/record.url?scp=33846458243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846458243&partnerID=8YFLogxK

U2 - 10.1001/archinte.167.2.161

DO - 10.1001/archinte.167.2.161

M3 - Article

VL - 167

SP - 161

EP - 165

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 2

ER -